Accelerating research by connecting patients, data and researchers
RareCan works with biotech and pharmaceutical companies, contract research organisations and academic research teams to accelerate discovery, translation and clinical trials of precision cancer treatment and diagnostics. We focus on delivering patient-centric solutions that accelerate pre-clinical and clinical programmes thereby increasing return on investment for our clients by reducing time to licencing and increasing time for marketing under patent – and ultimately increasing treatment options for patients with rarer types of cancer.
Empower Every Patient: Become a sponsor of our clinical trial matching service
Services
Bespoke clinical trial services
Patient-centric services delivering value throughout the trial life-cycle, including site selection, recruitment and retention.
Precision medicine platform
A subscription service delivering clinically- and genetically-prescreened patients for gene-targeted therapy programmes.
BioResource services
Bespoke services for collection, processing, analysis and storage of tumour and blood samples for pre-clinical and clinical trials.
Patient insights
Connecting clients with engaged rare cancer patients, and providing expert support for patient consultation, focus groups and patient surveys.
Why work with RareCan?
Together for the Cure: Your Drugs, Our Patient Data, A World of Possibilities
Why work with RareCan?
Together for the Cure: Your Drugs, Our Patient Data, A World of Possibilities
What makes us different?
- Patient-centric, consent-driven platform
- Partnerships with multiple patient advocacy groups
- Deep multimodal characterisation & longitudinal data
- Bespoke innovative recruitment solutions
How do we add value?
- Rare cancer focus & expertise
- Increase speed of patient identification
- Increase speed & accuracy of screening
- Reduce screen failure rates
- Increase retention rates
Our partners
We collaborate with partners across the healthcare system to support patients with rare cancers.
